No quarterly revenue total was found in Hemab Therapeutics Holdings, Inc.'s SEC filings.
Hemab Therapeutics Holdings, Inc. (COAG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$22.7 million. As of Jun 30, 2026 it held $457.5 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income
$-24.15M
-6.4% vs prior quarter
Operating cash flow
$-22.64M
-4.9% vs prior quarter
Free cash flow
$-22.66M
-4.4% vs prior quarter
EPS
$-0.80
+96.7% vs prior quarter
Dividend per share
None
Shares outstanding
46.71M
+0.0% vs prior quarter
Net cash
$456.43M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- COAG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2114044
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Operating income | -$26.1M | -$23.6M |
| Net income | -$24.1M | -$22.7M |
| Diluted EPS | -$0.80 | -$23.98 |
| Operating cash flow | -$22.6M | -$21.6M |
| Free cash flow | -$22.7M | -$21.7M |
| Total assets | $467.8M | $175.3M |
| Total liabilities | $13.5M | $13.7M |
| Stockholders' equity | $454.3M | -$198.6M |
| Cash and investments | $457.5M | $163.5M |
| Total debt | $1.0M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | May 21, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change
|
May 11, 2026 | May 8, 2026 |
All 50 Hemab Therapeutics Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.